Ionis Pharmaceuticals (NASDAQ:IONS) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Ionis Pharmaceuticals (NASDAQ:IONS) released its quarterly earnings data on Tuesday. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.12, Briefing.com reports. The business had revenue of $119.00 million during the quarter, compared to analysts’ expectations of $131.42 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The firm’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.87) EPS.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock traded up $0.24 during trading on Friday, hitting $39.71. The company had a trading volume of 22,799 shares, compared to its average volume of 1,111,263. Ionis Pharmaceuticals has a 52 week low of $34.99 and a 52 week high of $54.44. The stock has a market capitalization of $5.79 billion, a price-to-earnings ratio of -15.42 and a beta of 0.41. The company has a quick ratio of 5.83, a current ratio of 5.90 and a debt-to-equity ratio of 3.18. The stock’s 50-day moving average is $42.62 and its two-hundred day moving average is $46.82.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total transaction of $166,649.60. Following the completion of the sale, the executive vice president now directly owns 19,631 shares in the company, valued at $816,649.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Joseph Baroldi sold 4,006 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the transaction, the executive vice president now directly owns 19,631 shares of the company’s stock, valued at $816,649.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Joseph Klein III sold 6,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $42.71, for a total transaction of $256,260.00. Following the completion of the sale, the director now directly owns 16,346 shares in the company, valued at approximately $698,137.66. The disclosure for this sale can be found here. Insiders have sold 10,393 shares of company stock valued at $440,127 in the last quarter. Insiders own 2.65% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday. Wells Fargo & Company lowered their price target on shares of Ionis Pharmaceuticals from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Wednesday. Wolfe Research raised shares of Ionis Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $58.00 price objective on the stock in a research note on Wednesday, April 10th. Oppenheimer lifted their target price on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 9th. Finally, JPMorgan Chase & Co. increased their price target on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $59.54.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.